Thousands of people with multiple sclerosis in England are set to gain access to a drug that could help some patients walk faster and for longer, marking a major shift in how one of the disease's most disabling symptoms is managed.
Fampridine, also known as Fampyra, is being rolled out through the National Health Service as the first licensed medicine specifically intended to improve walking ability in people with MS. Health officials say about 5,000 patients could be eligible for the treatment in its first year.
The move has been welcomed by MS advocates, who say even a modest improvement in mobility can make a significant difference to a person's independence, confidence and ability to carry out everyday activities.
A 'Signal Booster' for Damaged Nerves
MS is an incurable autoimmune disease in which the immune system mistakenly attacks the central nervous system, damaging the protective covering around nerve fibers and disrupting communication between the brain and the rest of the body.
Walking impairment is among the most consequential symptoms for many people with MS. Until now, treatment options have largely focused on rehabilitation, physiotherapy, walking aids and devices designed to support mobility.
Fampridine works differently. The medication is designed to help improve the transmission of electrical signals along nerves damaged by MS, potentially allowing signals involved in muscle movement to travel more effectively.
According to the NHS, clinical trials found that 43% of patients who took fampridine experienced an improvement in walking speed, while some were also able to walk for longer.
The drug does not reverse the underlying nerve damage caused by MS, nor is it a cure for the disease. Instead, it targets mobility, offering some patients the possibility of regaining function that may have become increasingly difficult to maintain.
EDSS Scores that Can Qualify for the Drug
The NHS rollout will initially focus on people with MS whose disability falls within a specific range on the Expanded Disability Status Scale (EDSS), which doctors use to assess how the disease affects mobility and other functions.
Patients with EDSS scores from 4 to 7 may be considered for treatment. The range includes people who can still walk independently but have significant limitations, as well as those who rely on mobility aids or have severely restricted walking ability.
Eligible patients will take fampridine twice a day during an initial trial lasting about two to four weeks. Their walking ability will be assessed before and after starting the medication to determine whether they are responding.
Those who demonstrate a meaningful improvement can continue treatment under regular medical review.
Patients Hope for More Freedom
For people living with MS, the impact of improved mobility can extend far beyond walking speed.
NHS national medical director Professor Frankie Swords said the treatment could help some patients move around their homes more easily, venture outside with greater confidence and maintain greater independence.
"Walking difficulties can have a huge impact on the freedom and independence of people with MS, so this signal-boosting pill could be life-changing for thousands of patients."
The NHS rollout could allow patients like to access a treatment they previously could not afford.
The MS Society also welcomed the decision, emphasizing that fampridine is currently the only licensed treatment specifically intended to improve walking ability and speed for some people with MS.
A New Focus on Mobility
An estimated 2.9 million people worldwide are living with multiple sclerosis. In the US, a landmark study supported by the National Multiple Sclerosis Society found that nearly 1 million Americans have MS.
The drug's arrival does not change the broader reality of MS, but for those who respond to treatment, researchers and advocates say improved walking could translate into greater independence and a better ability to participate in work, family life and daily activities.
The rollout also underscores a growing focus on treating the functional consequences of MS alongside the disease itself. For patients who have watched their mobility gradually disappear, the possibility of walking farther, moving more confidently or relying less on assistance could represent a meaningful change in everyday life.
